Evidence map›Paper›PMID 32566045›Full record

ReviewInflammation and regeneration2020

Review: transcriptome and trans-omics analysis of systemic lupus erythematosus.

Keishi Fujio, Yusuke Takeshima, Masahiro Nakano, Yukiko Iwasaki

Open access · goldAbstract readReview
PubMed Full text at PMC Publisher
In one paragraph

Review in Inflammation and regeneration, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed
1.2field-weighted citation impact, top 20% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed, 8 citations in OpenAlex.

  1. Review
  2. Article
  3. Article
  4. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

4 authors at 1 institution in 1 country.

Keishi FujioDepartment of Allergy and Rheumatology, Graduate School of Medicine, The University of Tokyo, 113-8655 7-3-1 Hongo, Bunkyo-ku, Tokyo, Japan.
Yusuke TakeshimaDepartment of Allergy and Rheumatology, Graduate School of Medicine, The University of Tokyo, 113-8655 7-3-1 Hongo, Bunkyo-ku, Tokyo, Japan.
Masahiro NakanoDepartment of Allergy and Rheumatology, Graduate School of Medicine, The University of Tokyo, 113-8655 7-3-1 Hongo, Bunkyo-ku, Tokyo, Japan.
Yukiko IwasakiDepartment of Allergy and Rheumatology, Graduate School of Medicine, The University of Tokyo, 113-8655 7-3-1 Hongo, Bunkyo-ku, Tokyo, Japan.
The University of Tokyo · JP

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Systemic lupus erythematosus (SLE), which was recognized as a defined clinical entity more than 100 years ago, is an archetype for systemic autoimmune diseases. The 10-year survival of SLE patients has shown dramatic improvement during the last half-century. However, SLE patients receiving long-term prednisone therapy are at high risk of morbidity due to organ damage. Identification of key immune pathways is mandatory to develop a suitable therapy and to stratify patients based on their responses to therapy. Recently developed transcriptome and omic analyses have revealed a number of immune pathways associated with systemic autoimmunity. In addition to type I interferon, plasmablast and neutrophil signatures demonstrate associations with the SLE phenotype. Systematic investigations of these findings enable us to understand and stratify SLE according to the clinical and immunological features.

Indexed as

eQTLOmicsSystemic lupus erythematosusTranscriptome

Identifiers

PMID32566045
PMCPMC7301441
OpenAlexW3036523401

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.